Preoperative MELD, MELD-Na and MELD-XI Scores as Predictors of Mortality and Morbidity after LVAD Implantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040329

Enrollment

120

Registered

2026-07-23

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50

Interventions

Group 1: This retrospective study includes all patients who underwent LVAD implantation at the Department of Cardiac Surgery at the University Hospital Düsseldorf between 2010 and 2017

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult patients (aged 18 years or older) who have successfully undergone LVAD implantation (e.g., HeartMate 3, HeartWare HVAD) as a bridge-to-transplant or destination therapy.

Exclusion criteria

Exclusion criteria: Pediatric cases, temporary RVAD/BiVAD, incomplete laboratory data

Design outcomes

Primary

Measure	Time frame
In-hospital mortality: Death during the index hospital stay following LVAD implantation 1-year all-cause mortality: Death within 365 days after surgery, regardless of cause	—

Secondary

Measure	Time frame
Intensive Care Unit (ICU) length of stay: Days from surgery to transfer to a general ward Hospital length of stay: Days from surgery to discharge Reoperations: All invasive revisions within 30 days (bleeding, tamponade, infection) Right ventricular failure (RVF): According to the INTERMACS definition—need for RVAD, NO/inotropes >14 days, or ECHO criteria (RVSP >50 mmHg, TAPSE <10 mm) Major bleeding (BARC =3): According to Bleeding Academic Research Consortium (BARC) classification, types 3–5 Renal replacement therapy (RRT): CVVH/CVVHD/dialysis =1 time during hospitalization	—

Measure

Time frame

Intensive Care Unit (ICU) length of stay: Days from surgery to transfer to a general ward Hospital length of stay: Days from surgery to discharge Reoperations: All invasive revisions within 30 days (bleeding, tamponade, infection) Right ventricular failure (RVF): According to the INTERMACS definition—need for RVAD, NO/inotropes >14 days, or ECHO criteria (RVSP >50 mmHg, TAPSE <10 mm) Major bleeding (BARC =3): According to Bleeding Academic Research Consortium (BARC) classification, types 3–5 Renal replacement therapy (RRT): CVVH/CVVHD/dialysis =1 time during hospitalization

—

Countries

Germany

Contacts

Public ContactHannan Dalyanoglu

Klinik für Herzchirurgie

hannan.dalyanoglu@med.uni-duesseldorf.de02118107108

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026